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Abstract  
 
The purpose of this study was to assess the efficacy of arterial-dominant phase images 
of gadolinium–ethoxybenzyl–diethylenetriamine pentaacetic acid (EOB)-enhanced 
magnetic resonance imaging (MRI) for evaluation of arterial blood supply in 
hepatocellular carcinoma (HCC) in comparison with that of multiphasic dynamic 
computed tomography (CT). This study comprised 30 patients (22 men and 8 women, 
mean age: 68.0 years) with 40 pathologically proven HCCs (well differentiated: 3, 
moderately differentiated: 30, poorly differentiated: 7, mean diameter: 45.1 mm), all of 
whom underwent EOB-enhanced MRI and dynamic CT preoperative assessment. 
Regions of interest were placed over HCCs and the adjacent normal liver, and signal 
intensities or CT values were measured by two experienced abdominal radiologists on 
the arterial-dominant phase images of EOB-enhanced MRI and dynamic CT images. 
HCC-to-liver contrasts [Michelson's contrast: CM=(SHCC− SLiver)/(SHCC+ SLiver)] were 
calculated and compared among the modalities. HCC-to-liver contrasts were also 
visually scored on a 5-point scale and compared. The mean CM and visual score for 
dynamic CT were significantly higher than those for EOB-enhanced MRI. Good 
agreements were obtained among the two observers. Dynamic CT is a more suitable 
modality than EOB-enhanced MRI for evaluation of arterial blood supply in HCC. This 
should be taken into account for diagnosis and management of HCC. 
 
Keywords:Arterial blood supply, Computed tomography, Contrast, EOB, Hepatocellular 
carcinoma, Magnetic resonance imaging 
 
  
 
 
 
 
 
 
 
 
 
 
 
1. Introduction  
Hepatocellular carcinoma (HCC) is causing approximately 600,000 to 700,000 deaths 
annually worldwide. It is highly prevalent in the Asia-Pacific region and Africa and is on 
the increase in Western countries, so early detection, accurate diagnosis and proper 
management are urgently required on a global scale. The evaluation of arterial blood 
supply (i.e., vascularity or vascular pattern) in tumor is an essential step for both 
diagnosis and management of HCC [1-4], and it is usually performed by means of 
multiphasic contrast-enhanced dynamic computed tomography (CT) and magnetic 
resonance imaging (MRI) with intravenous bolus injection of contrast medium. 
A recently available liver-specific contrast medium, gadolinium–ethoxybenzyl–
diethylenetriamine pentaacetic acid (EOB), reportedly has a high diagnostic capability 
for detection of malignant liver tumors. It works as both an extracellular and hepatocyte-
specific contrast agent and provides both dynamic and hepatocyte-specific imaging. 
However, its diagnostic capability for HCC is reportedly only slightly better or equal to 
that of dynamic CT [5-11]. Possible reasons for this are that the administrated volume 
of EOB is smaller than that of extracellular gadolinium contrast media and its 
concentration of gadolinium is only about half. Therefore, HCC-to-liver contrast can be 
assumed to be lower on arterial phase images of EOB-enhanced MRI than that on 
arterial phase images of dynamic CT or MRI using extracellular gadolinium contrast 
media, thus resulting in a lower detection rate of HCC and lower ability to assess 
hypervascularity. However, no objective studies dealing with this issue have been 
reported. 
The purpose of this study was thus to assess the efficacy of EOB-enhanced MRI for 
evaluation of arterial blood supply in HCC in comparison with that of multiphasic 
dynamic CT. 
 
 
2. Materials and methods  
 
2.1. Patients  
A total of 45 patients prospectively underwent all three examinations of Gd-EOB-
DTPA-enhanced MRI and contrast-enhanced multiphasic dynamic CT of the liver for 
preoperative assessment between January 2010 and November 2010. Fifteen patients 
whose diagnosis of HCC was not confirmed histopathologically were excluded from the 
study population, so 30 patients (22 males, 8 females; mean age: 68.0 years) were 
considered eligible for this study. Twenty-five patients were diagnosed with chronic 
hepatitis virus infection (8 with hepatitis B and 17 with hepatitis C). Three patients had 
ethanol-induced and one had nonalcoholic steatohepatitis. In one patient, the etiology of 
the chronic liver disease was unknown. All patients were classified as Child–Pugh A. 
None of them had previously undergone hepatobiliary surgery or transarterial 
chemoembolization. All patients underwent the two examinations and hepatectomy 
within 1 month. Mean body weight of the patients was 58.7±10.4 kg (range: 41.2–76.5). 
Consequently, this study included 40 histopathologically proven HCCs (well 
differentiated: 3, moderately differentiated: 30, poorly differentiated: 7). The diameters 
of the tumors ranged from 13 to 130 mm with a mean of 45.1±29.8 mm. 
This study was approved by the local ethics committee of our institution, and 
informed consent was obtained from all participating patients. 
 
2.2. Magnetic resonance imaging  
EOB-enhanced MR examination was performed with a superconducting imager 
operating at 1.5 T (Achieva; Philips Medical Systems, Best, the Netherlands) and using 
a four-element phase-array body coil. Precontrast axial T1-weighted gradient-echo 
images were obtained with fat suppression [repetition time (TR)/echo time (TE): 210/4.6 
ms; flip angle (FA): 75°] and without it (TR/TE: 235/4.6 and 2.3 ms; FA=75°). A 
multiphasic dual-arterial dynamic study was performed using three-dimensional T1-
weighted gradient-echo (TR/TE/FA: 2.25–3.09 ms/0.8–1.5 ms/10°–15°; matrix size: 
224×168; field of view: 380–400 mm; number of excitations: 1; slice thickness: 8 mm; 
transverse slices: 22–30; for fat saturation: spectral presaturation with inversion 
recovery; parallel imaging factor: 2.0; scan time: 7 s) with intravenous bolus injection of 
25 μmol/kg (0.1 ml/kg) of Gd-EOB-DTPA (Primovist; Bayer Healthcare, Osaka, Japan) 
by means of a power injector (Sonic Shot 50; Nemoto Kyorindo Co. Ltd., Tokyo, Japan) 
at a rate of 2 ml/s, followed by 30 ml of saline chaser at the same rate during breath 
holding. The scan delays were set at 20 s after the start of injection, and dual-arterial 
dynamic images were obtained serially during a single breathhold. Portal- and delayed-
phase images were also obtained 60 and 90 s after injection. 
Twenty minutes after injection, T1-weighted images with fat suppression were 
repeated as hepatobiliary phase images, and breath-hold T2-weighted fast spin-echo 
images (TR/TE=2800 ms/90 ms) were obtained. A slice thickness was set at 8 mm for all 
the sequences. 
 
2.3. Multiphasic dynamic CT  
CT examination was performed by using a 64-detector-row CT system (Aquilion 64; 
Toshiba Medical System, Ohtawara, Japan) with the following parameters: 64×0.5-mm 
detector collimation, reconstructed to axial slices with a thickness of 5 mm, 0.5-s/gantry 
rotation, 120 kVp and 0.94 beam pitch. The tube current was set by automated exposure 
control (noise level: 10). Each subject was first examined with unenhanced CT, and this 
was followed by the injection of iodinated contrast medium (Iomeron 350; Eisai Co. Ltd., 
Tokyo, Japan) with a power injector (Dual Shot GX; Nemoto Kyorindo). Injection dose 
was 600 mg iodine per kg of body weight, and since duration was fixed at 25 s, the 
injection rate depended on the patient's body weight. An upper limit of injection rate was 
set at 5 ml/s. In three patients whose body weight was more than 72.9 kg, injection 
duration exceeded 25 s. No saline chaser was administered. 
A bolus tracking program was used to optimize the scanning delay for dual-arterial 
dynamic scans. The trigger point was placed at the abdominal aorta at the level of the 
celiac axis, and the trigger threshold was set at an increase in CT number of more than 
200 Hounsfield units over the baseline value. The scan delays were set at 5 s after the 
trigger, and dual-arterial dynamic images were obtained serially during a single 
breathhold. Portal- and delayed-phase images were also obtained 70 and 150 s after 
injection. 
 
2.4. Image analysis  
 
2.4.1. Image and phase selections  
Two experienced abdominal radiologists (T. K., T. Y.) with 8 and 17 years of experience, 
respectively, independently reviewed the axial images from the three examinations of all 
30 patients at a picture archiving and communication system workstation (ShadeQuest; 
Yokogawa Electric Corporation, Musashino, Japan) while blinded to the 
histopathological diagnosis. First, the observers were asked to select the images with 
HCCs shown at their maximal diameter. Second, the observers were also asked to select 
the phase with the higher HCC-to-liver contrast from the first and second arterial-
dominant phase images of dynamic CT and EOB-enhanced MRI for each patient. The 
selected phases and images were then used for further analyses. 
 
2.4.2. Quantitative analysis  
The quantitative analysis was conducted by the two observers on the images obtained 
with all the examinations using the operator-defined region-of-interest (ROI) 
measurements of mean signal intensity or CT value of HCC and surrounding normal 
liver parenchyma. The oval ROI was placed within HCC and made as large as possible 
to include necrotic areas for calculation of overall HCC-to-liver contrast and the visually 
selected maximal enhancement area (5% to 10% of the total tumor area) for calculation 
of maximal HCC-to-liver contrast. The ROI for surrounding normal liver parenchyma 
was at least 5 cm2 and located adjacent to the target lesion, while vessels were avoided 
as much as possible. The ROIs were placed in the same locations between the 
examinations as far as possible. Fig. 1, Fig. 2 show examples of ROI placements. 
The definition of contrast used in this study is known as Michelson's contrast (CM) 
and is defined as: 
 
Where SHCC is the signal intensity or CT value of the HCC and SLiver is the signal 
intensity or CT value of the surrounding normal liver parenchyma. The mean overall 
HCC-to-liver contrasts and mean maximal HCC-to-liver contrasts obtained with the two 
examinations were then calculated and compared. Michelson's contrast has been 
commonly used in the field of optics (e.g., luminance contrast) and has recently been 
introduced to the field of radiology [12,13]. This approach enables the calculation of 
absolute contrast on each image, and direct comparisons of each arterial-dominant phase 
image are possible, though information of degree of enhancement is lost. 
 
2.4.3. Qualitative analysis  
For each patient, the observers subjectively scored the degree of HCC-to-liver 
contrast according to the following 5-point scale: 1, signal intensities or CT values of 
HCC are lower than those of surrounding normal liver; 2, signal intensities or CT values 
of HCC are equal to those of surrounding normal liver; 3, signal intensities or CT values 
of HCC are slightly higher than those of surrounding normal liver; 4, signal intensities 
or CT values of HCC are noticeably higher than those of surrounding normal liver; 5, 
signal intensities or CT values of HCC are markedly higher than those of surrounding 
normal liver. The mean visual scores for HCC-to-liver contrast for the three modalities 
were then calculated and compared. 
 
2.4.4. Statistical analysis  
Statistical analysis of the mean HCC-to-liver contrast (CM) was performed with the 
aid of one-way analysis of variance and the Scheffé criterion. For statistical analysis of 
the mean visual scores for HCC-to-liver contrast, the Kruskal–Wallis test and Scheffé 
criterion were used. All of the quantitative and qualitative values were expressed as 
mean±S.D. For all tests, a P value of less than .05 was considered statistically significant. 
For the qualitative analysis, interobserver agreements were analyzed by means of κ 
statistics. Positive correlation was considered to be indicated by a κ value greater than 
0, poor correlation by values of 0.00–0.01, low correlation by values of 0.01–0.20, 
moderate correlation by values of 0.21–0.40, good correlation by values of 0.41–0.60, 
substantial correlation by values of 0.61–0.80 and almost perfect agreement by values 
greater than 0.81. 
 
3. Results  
HCC-to-liver contrasts were visually higher on the second arterial-dominant phase 
images of both EOB-enhanced MRI and dynamic CT for all patients, so only these images 
were used for further analyses. For both observers, the mean CM values of dynamic CT 
trended towards higher values than those of EOB-enhanced MRI (Table 1). For both 
observers, the mean maximal CMs of dynamic CT were significantly higher than those of 
EOB-enhanced MRI (Table 2). Finally, for both observers, the mean visual scores of 
dynamic CT were significantly higher than those of EOB-enhanced MRI (Table 3). 
Typical cases are shown in Fig. 1, Fig. 2. 
The κ values for the two observers were 0.80 for dynamic CT and 0.80 for EOB-
enhanced MRI, indicating that substantial to almost perfect agreements were obtained. 
 
 
 
 
 
 
 
 
 
 
 
 Fig. 1  
A 78-year-old man with HCC in the right posterior segment. Second arterial-dominant phase image of EOB-
enhanced MRI (A) shows heterogeneous and slight enhancement of the lesion. The visual score was 3. Second 
arterial-dominant phase image of contrast-enhanced dynamic CT (B) demonstrates heterogeneous and noticeable 
enhancement of the lesion. The visual score was 4. The ROIs were placed within HCC and made as large as possible 
to include necrotic areas, the visually selected maximal enhancement area and the surrounding normal liver 
parenchyma. Signal intensity and CT value were measured, and HCC-to-liver contrasts were calculated. The latter 
were 0.20 for EOB-enhanced MRI and 0.29 for dynamic CT. Maximal HCC-to-liver contrasts were also calculated 
and were 0.33 for EOB-enhanced MRI and 0.37 for dynamic CT. 
 
Fig. 2  
A 75-year-old man with HCC in the left medial segment. Second arterial-dominant phase image of EOB-enhanced 
MRI (A) shows heterogeneous and slight enhancement of the lesion. The visual score was 3. Second arterial-
dominant phase image of contrast-enhanced dynamic CT (B) demonstrates heterogeneous and noticeably higher 
enhancement of the lesion. The visual score was 4. HCC-to-liver contrasts were calculated and were 0.13 for EOB-
enhanced MRI and 0.28 for dynamic CT. Maximal HCC-to-liver contrasts were also calculated and were 0.21 for 
EOB-enhanced MRI and 0.38 for dynamic CT. 
Table 1. Mean overall HCC-to-liver contrasts for the two modalitiesa 
 
 Dynamic CT EOB-MRI 
Observer 1 0.19 ± 0.11 0.13 ± 0.13 
Observer 2 0.19 ± 0.10 0.13 ± 0.14 
 
Dynamic CT: second arterial-dominant phase of multiphasic contrast-enhanced dynamic CT; EOB-MRI: second 
arterial-dominant phase of EOB-enhanced MRI. 
aMichelson's contrast: CM=(SHCC−SLiver)/(SHCC+SLiver). 
 
 
Table 2. Mean maximal HCC-to-liver contrasts for the two modalitiesa 
 Dynamic CT EOB-MRI 
Observer 1 0.29 ± 0.10* 0.19 ± 0.12 
Observer 2 0.30 ± 0.09** 0.20 ± 0.14 
aMichelson's contrast: CM=(SHCC−SLiver)/(SHCC+SLiver). 
Mean HCC-to-liver contrast was significantly higher than that for EOB-enhanced MRI (P<.005). 
Mean HCC-to-liver contrast was significantly higher than that for EOB-enhanced MRI (P<.05).  
 
 
Table 3. Mean visual scores for HCC-to-liver contrasts for the two modalities 
 Dynamic CT EOB-MRI 
Observer 1 3.5 ± 1.1* 2.5 ± 0.9 
Observer 2 3.7 ± 1.1** 2.6 ± 1.0 
Mean visual score for HCC-to-liver contrast was significantly higher than that for EOB-enhanced MRI 
(P<.001). 
Mean visual score for HCC-to-liver contrast was significantly higher than that for EOB-enhanced MRI 
(P<.0005). 
 
 
 
 
 
 
 
 
 
4. Discussion  
For early detection, accurate diagnosis and proper management of HCC, the 
evaluation of arterial blood supply in tumor is essential. This evaluation is commonly 
performed using either multiphasic dynamic CT or MRI with intravenous bolus injection 
of contrast medium [1-4]. Recently, Gd-EOB-DTPA has come to play a major role in the 
diagnosis of HCC because it functions as both an extracellular and hepatocyte-specific 
contrast agent and provides both dynamic and hepatocyte-specific information. 
However, the overall diagnostic capability of Gd-EOB-DTPA for HCC is reportedly 
only slightly better than or equal to dynamic CT [5-11] — except for the evaluation in 
one recently published report [13] — in spite of the use of hepatobiliary phase images, 
which were found to improve the diagnostic ability of EOB-enhanced MRI [14-17]. 
Possible reasons for this are that the administrated volume of EOB (0.025 mmol/kg) is 
smaller than that of extracellular gadolinium contrast media (0.05 mmol/kg) and its 
concentration of gadolinium is only about half. Although this is partially compensated 
for by the higher T1 relaxivity of Gd-EOB-DTPA, enhancement of HCC in the arterial-
dominant phase decreases, resulting in lower HCC-to-liver contrast on arterial phase 
images. Akai et al. visually compared the arterial phase images of EOB-enhanced MRI 
with those obtained with dynamic CT and reported that the former were slightly inferior 
to the latter for evaluation of vascularity in HCC, although the difference was not 
significant [9]. However, this study covered only a small patient population and used 
subjective assessment. As for enhancement of the liver parenchyma, Tamada et al. 
reported that signal intensity ratio of the liver on EOB-enhanced arterial phase image 
was significantly lower than that of Gd-DTPA for normal subjects [18], and Filippone et 
al. reported reduced enhancement of EOB for both cirrhotic and noncirrhotic liver 
compared to Gd-DTPA [19]. 
On the other hand, dynamic CT techniques have rapidly improved and become 
optimized in recent years. We therefore hypothesized that dynamic CT was superior to 
EOB-enhanced MRI for evaluation of arterial blood supply in HCC. 
In addition, previous relevant reports mainly used subjective methods of assessment. 
A comparative study using both subjective and objective methods for assessment across 
the various modalities was therefore needed. However, direct comparison of the degree 
of tumor enhancement by the various modalities is impossible because the mechanisms 
for image reconstruction and contrast enhancement are completely different. To 
overcome this problem, we introduced an index known as Michelson's contrast (CM), 
which has recently been introduced to the field of radiology [12]. With this index, we can 
compare tumor-to-normal tissue contrasts on images obtained with the modalities, and 
this contrast is the most important factor for detection of HCC and evaluation of its 
vascular pattern for routine image interpretations. The results of quantitative and 
qualitative analyses showed good correlation, indicating that the use of CM for this 
purpose is satisfactory. 
Our results showed that both observers in our study rated the mean CM of dynamic 
CT as significantly higher than that of EOB-enhanced MRI when using maximal HCC-
to-liver contrast was used. This was confirmed by our qualitative analysis and suggests 
that EOB-enhanced MRI is suboptimal for evaluating arterial blood supply when 
compared to dynamic CT; however, further studies with assessment of diagnostic 
accuracy are needed to confirm our results. This should be taken into account for 
diagnosis and management of HCC, and when using EOB-enhanced MRI, injection 
techniques should be optimized or administration doses should be reviewed [18]. 
The imaging and contrast enhancement techniques used in this study were somewhat 
different for the different modalities. Saline chaser was not used for dynamic CT, which 
resulted in underestimation of the efficacy of dynamic CT. Moreover, we did not use a 
bolus tracking technique for EOB-enhanced MRI, and the scan timing of arterial phase 
images may not have been appropriate. However, the latter is not a major limitation 
because we used a dual-arterial phasic protocol which is reportedly quite adequate for 
scan timing [11]. 
There are some limitations to this study. First, the number of patients involved was 
rather small, so further studies with larger populations are needed to verify our results. 
Second, HCCs in our study were rather large, resulting in insufficient data for smaller 
lesions. However, quantitative assessment of small lesions can be adversely affected by 
partial volume averaging. In addition, it is difficult to obtain accurate pathological 
diagnosis for small lesions because biopsy is often difficult and it is often interpreted as 
intrahepatic metastasis, which prevents the patient from benefiting from curative 
surgery. Finally, our study did not evaluate diagnostic accuracy of both modalities. 
In conclusion, dynamic CT is a more suitable modality than EOB-enhanced MRI for 
evaluation of arterial blood supply in HCC. This should be taken into account for 
diagnosis and management of HCC 
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